SEC Hits Allarity With Wells Notice, Flags Alleged Violations in FDA Meeting

Allarity Therapeutics announced Monday that the Securities and Exchange Commission has made a preliminary determination recommending an enforcement action against the company for alleged violations of federal securities laws.